Effects of Fenofibrate Treatment on Cardiovascular Disease Risk in 9,795 Individuals With Type 2 Diabetes and Various Components of the Metabolic Syndrome
Open accessThe DOI matches its Crossref record; 24 of the 26 references it cites were found in a registry or an index.
Abstract
OBJECTIVE—We explored whether cardiovascular disease (CVD) risk and the effects of fenofibrate differed in subjects with and without metabolic syndrome and according to various features of metabolic syndrome defined by the Adult Treatment Panel III (ATP III) in subjects with type 2 diabetes in the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. RESEARCH DESIGN AND METHODS—The prevalence of metabolic syndrome and its features was calculated. Cox proportional models adjusted for age, sex, CVD status, and baseline A1C levels were used to determine the independent contributions of metabolic syndrome features to total CVD event rates and the effects of fenofibrate. RESULTS—More than 80% of FIELD participants met the ATP III criteria for metabolic syndrome. Each ATP III feature of metabolic syndrome, apart from increased waist circumference, increased the absolute risk of CVD events over 5 years by at least 3%. Those with marked dyslipidemia (elevated triglycerides ≥2.3 mmol/l and low HDL cholesterol) were at the highest risk of CVD (17.8% over 5 years). Fenofibrate significantly reduced CVD events in those with low HDL cholesterol or hypertension. The largest effect of fenofibrate to reduce CVD risk was observed in subjects with marked dyslipidemia in whom a 27% relative risk reduction (95% CI 9–42, P = 0.005; number needed to treat = 23) was observed. Subjects with no prior CVD had greater risk reductions than the entire group. CONCLUSIONS—Metabolic syndrome components identify higher CVD risk in individuals with type 2 diabetes, so the absolute benefits of fenofibrate are likely to be greater when metabolic syndrome features are present. The highest risk and greatest benefits of fenofibrate are seen among those with marked hypertriglyceridemia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Potential use of fibrates to reduce TG levels is quite limited, due to the risk of myopathy if given with statins and the little benefit demonstrated in RCTs, aside from sub-group analysis including subjects with very high TG levels.200,270,271”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [270]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Specifically, the five year FIELD Study, which evaluated 9,795 subjects with type 2 diabetes who were 50–75 years of age, demonstrated a reduction of 24% of non-fatal myocardial infraction (MI) for those receiving FF-compared to placebo (p=0.01).”
From Fenofibrate and metabolic syndrome (2010) · cites this paper as [46]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“However, a post hoc analysis of data from the FIELD study suggested a benefit for patients with both elevated triglyceride levels and low HDL cholesterol levels.12”
From Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus (2010) · cites this paper as [12]
The cited source says what the claim attributes to it.
In the citing paper
“Elevation of TGs or low HDL-C is seen in about half of subjects with T2DM. 351”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [351]
The cited source says what the claim attributes to it.
In the citing paper
“In a post hoc analysis of the FIELD study, fenofibrate reduced CVD events by 27% in those with elevated TGs [>2.3 mmol/L (~204 mg/dL)] and reduced HDL-C (NNT ¼ 23).351”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [351]
11 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Toprak, O., Kurt, H., Sarı, Y., Şarkış, C., Us, H., & Kırık, A. (2017) · Kidney and Blood Pressure Research · doi:10.1159/000468530 · Cited by 29,627
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,947
Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
Collaborators, C. T. T. (. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60104-x · Cited by 2,081
Nordestgaard, B. G., Benn, M., Schnohr, P., & Tybjærg-Hansen, A. (2007) · JAMA · doi:10.1001/jama.298.3.299 · Cited by 2,058
Hokanson, J. E., & Austin, M. A. (1996) · Journal of Cardiovascular Risk · doi:10.1097/00043798-199604000-00014 · Cited by 1,706
Alexander, C. M., Landsman, P. B., Teutsch, S. M., & Haffner, S. M. (2003) · Diabetes · doi:10.2337/diabetes.52.5.1210 · Cited by 1,475 · cited 1×
“National Health and Nutrition Examination Survey III survey and also in individuals with newly diagnosed diabetes (11,12).”
BackgroundAtherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk
Austin, M. A., King, M. C., Vranizan, K. M., & Krauss, R. M. (1990) · Circulation · doi:10.1161/01.cir.82.2.495 · Cited by 1,411 · cited 1×
“ies (8,14), presumably reflecting a tendency for high nonfasting triglyceride levels and higher numbers of remnant particles and may be associated with more extreme abnormalities in other biological processes (such as oxidative stress, inflammation, and hypercoagulability), leading to more aggressive atherosclerosis (…”
BackgroundSarwar, N., Danesh, J., Eiriksdottir, G., Sigurdsson, G., Wareham, N., Bingham, S., Boekholdt, S. M., Khaw, K.-T., & Gudnason, V. (2007) · Circulation · doi:10.1161/circulationaha.106.637793 · Cited by 1,408 · cited 1×
“ies (8,14), presumably reflecting a tendency for high nonfasting triglyceride levels and higher numbers of remnant particles and may be associated with more extreme abnormalities in other biological processes (such as oxidative stress, inflammation, and hypercoagulability), leading to more aggressive atherosclerosis (…”
Background
Cited by
Items 301–400 of 549
Jun, J. E., Jeong, I., Yu, J. M., Kim, S. R., Lee, I. K., Han, K. A., Choi, S. H., Kim, S., Park, H. K., Mok, J., et al. (2019) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2018.0265 · Cited by 19
Foucher, C., Aubonnet, P., Reichert, P., Berli, M. A., Schaeffer, A., Vargas, C. G. C., Lochocka, A., Belenky, D., Koch, H., & the Cholib study Investigators (2015) · Cardiovascular Therapeutics · doi:10.1111/1755-5922.12148 · Cited by 15
Oral fenofibrate in neonatal hyperbilirubinemia: A randomized controlled trial
Chaudhary, G. S., Chaudhary, V., Chaurasiya, O. S., Chandrakant, V., & Kumar, V. (2016) · Indian Journal of Child Health · doi:10.32677/ijch.2016.v03.i01.012 · Cited by 12
Omega-3 carboxylic acids monotherapy and combination with statins in the management of dyslipidemia
Benes, L. B., Bassi, N. S., & Davidson, M. H. (2016) · Vascular Health and Risk Management · doi:10.2147/vhrm.s58149 · Cited by 13
Horikawa, T., Kawanami, T., Hamaguchi, Y., Tanaka, Y., Kita, S., Ryorin, R., Takashi, Y., Takahashi, H., Tanabe, M., Yanase, T., et al. (2020) · Heliyon · doi:10.1016/j.heliyon.2020.e05431 · Cited by 12
Wu, J., Wang, Y., Wang, A., Xie, J., & Zhao, X. (2018) · Scientific Reports · doi:10.1038/s41598-018-24157-w · Cited by 11
Ren, Z., Li, Y., Liu, J., Li, H., Li, A., Hong, L., Cui, G., Sun, R., Wulasihan, M., Sun, J., et al. (2018) · Cellular Physiology and Biochemistry · doi:10.1159/000491973 · Cited by 13
Watts, G. F., & Karpe, F. (2011) · Postgraduate Medical Journal · doi:10.1136/pgmj.2010.204990rep · Cited by 15
Triglyceride and Cardiovascular Disease
Kim, M. (2013) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2013.2.1.1 · Cited by 13
Fenofibrate: A novel approach in treating uncomplicated neonatal hyperbilirubinemia?
Kumar, B., Agarwal, P., Chorishi, A., & Dhaneria, M. (2012) · Zenodo (CERN European Organization for Nuclear Research) · doi:10.5281/zenodo.8266551 · Cited by 11
Lipid lowering therapy in type 2 diabetes
Föger, B. (2011) · Wiener Medizinische Wochenschrift · doi:10.1007/s10354-011-0908-4 · Cited by 11
The lipid triad, or how to reduce residual cardiovascular risk?
Girard-Mauduit, S. (2010) · Annales d Endocrinologie · doi:10.1016/j.ando.2010.02.001 · Cited by 18
Cheng, Q., Sun, J., Zhong, H., Wang, Z., Liu, C., Zhou, S., & Deng, J. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1393333 · Cited by 18
Hong, S., Kim, K., Han, K., & Park, C. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02353-5 · Cited by 11
Obesity phenotypes and atherogenic dyslipidemias
Choe, H. J., Almas, T., Neeland, I. J., Lim, S. K., & Després, J. (2025) · European Journal of Clinical Investigation · doi:10.1111/eci.70151 · Cited by 18
Núñez-Cortés, J. M., Pedro‐Botet, J., & Pintó, X. (2010) · Medicina Clínica · doi:10.1016/j.medcli.2010.03.014 · Cited by 11
Residual Vascular Risk in T2DM: The Next Frontier
Michel, P., Sylvie, A., & Michel, F. (2011) · InTech eBooks · doi:10.5772/22716 · Cited by 10
Kelly, M. S., Beavers, C. J., Bucheit, J. D., Sisson, E. M., & Dixon, D. L. (2017) · Journal of clinical lipidology · doi:10.1016/j.jacl.2017.05.014 · Cited by 11
Mayer, O., Bruthans, J., Seidlerová, J., Karnosová, P., Vaněk, J., Hronová, M., Gelžinský, J., Cvíčela, M., Wohlfahrt, P., Cífková, R., et al. (2017) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2017.07.018 · Cited by 10
Lipid-lowering Therapies in Myositis
Mizus, M. C., & Tiniakou, E. (2020) · Current Rheumatology Reports · doi:10.1007/s11926-020-00942-3 · Cited by 11
Ramachandran, S., Abbas, A., Saraf, S., Raju, J., Jewkes, C., & Jones, A. F. (2012) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2011.0112 · Cited by 10
Summarizing the FIELD study: lessons from a ‘negative' trial
Tsimihodimos, V., Mikhailidis, D. P., & Elisaf, M. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.850075 · Cited by 10
The beneficial effects of HDL-C on atherosclerosis: rationale and clinical results
Santos‐Gallego, C. G., Torres, F., & Badimón, J. J. (2011) · Clinical Lipidology · doi:10.2217/clp.10.90 · Cited by 11
More Clinical Lessons from the FIELD Study
Fazio, S. (2009) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-008-6160-5 · Cited by 12
Diretriz Brasileira de Dislipidemias e Prevenção da Aterosclerose – 2025
Rached, F. H., Miname, M. H., Rocha, V. Z., Zimerman, A., Cesena, F. Y., Sposito, A. C., Santos, R. D., Behr, P. E. B., Bianco, H. T., Alves, R. J., et al. (2025) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20250640 · Cited by 97
What should we do about Hypertriglyceridemia in Coronary Artery Disease Patients?
Singh, A., Schwartzbard, A. Z., Gianos, E., Berger, J. S., & WEINTRAUB, H. S. (2012) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-012-0220-7 · Cited by 9
Jacobson, T. A. (2012) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.12.56 · Cited by 10
Contemporary and Novel Therapeutic Options for Hypertriglyceridemia
Bell, D. A., & Watts, G. F. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2015.08.001 · Cited by 10
Yanai, H., Katsuyama, H., & Hakoshima, M. (2021) · Cardiology Research · doi:10.14740/cr1333 · Cited by 9
Ferdinand, K. C., Davidson, M. H., Kelly, M. T., & Setze, C. M. (2012) · American Journal of Cardiovascular Drugs · doi:10.2165/11597940-000000000-00000 · Cited by 11
Why, when and how should hypertriglyceridemia be treated in the high-risk cardiovascular patient?
Watts, G. F., & Karpe, F. (2011) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.11.61 · Cited by 12
Toplak, H., Ludvik, B. H., Lechleitner, M., Dieplinger, H., Föger, B., Paulweber, B., Weber, T., Watschinger, B., Horn, S., Wascher, T. C., et al. (2016) · Wiener klinische Wochenschrift · doi:10.1007/s00508-016-0993-x · Cited by 15
Experimental and clinical pharmacology: PCSK9 inhibitors - clinical applications
Schmidli, R. S. (2016) · Australian Prescriber · doi:10.18773/austprescr.2016.061 · Cited by 9
Benes, L. B., Bassi, N. S., Kalot, M. A., & Davidson, M. H. (2018) · Cardiology Clinics · doi:10.1016/j.ccl.2017.12.009 · Cited by 10
Increased systolic blood pressure associated with hypertriglyceridemia in female Sprague-Dawley rats
Mogane, C., Mokotedi, L. P., Millen, A. M. E., & Michel, F. S. (2019) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2019-0121 · Cited by 9
Challenges in the treatment of hypertriglyceridemia: glass half empty or half full?
Sahebkar, A., & Watts, G. F. (2015) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2015.1045880 · Cited by 9
Nakashima, R., Ikeda, S., Shinohara, K., Matsumoto, S., Yoshida, D., Ono, Y., Nakashima, H., Miyamoto, R., Matsushima, S., Kishimoto, J., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-92933-6 · Cited by 15
Not all fibrates are made equal: Learning from biology and clinical trials
Zambon, A., Staels, B., Farnier, M., Vrablík, M., & Catapano, A. L. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.120555 · Cited by 8
Vera, A. S. D., Alemán, J. A., Segura‐Fragoso, A., de Esteban, J. P. M., Couso, F. J. L., Rabanal, M. D. S. G., Vera, L. A. D., & Matta-Solis, H. H. (2019) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2019.04.010 · Cited by 13
Yamagishi, K., Iso, H., Sairenchi, T., Irie, F., Takizawa, N., Koba, A., Tomizawa, T., & Ota, H. (2021) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.63081 · Cited by 8
Mohiuddin, S. M., Thakker, K. M., Setze, C. M., & Kelly, M. T. (2011) · Current Medical Research and Opinion · doi:10.1185/03007995.2011.569018 · Cited by 8
de Expertos, G. D. T. D. D. A. D. L. S. E. D. A. Y. G. E. (2017) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2016.12.001 · Cited by 13
Al-Sabti, H. A., Al-Hinai, A. T., Al-Zakwani, I. S., Al-Hashmi, K., Almahmeed, W. A., Arafah, M., Shehab, A. M., Tamimi, O. A., Alawadhi, M., Herz, S. A., et al. (2022) · Oman Medical Journal · doi:10.5001/omj.2022.79 · Cited by 9
Wang, J., Shen, X., He, S., An, Y., Gong, Q., Li, H., Zhang, B., Shuai, Y., Chen, Y., Hu, Y., et al. (2019) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3163 · Cited by 9
Pedro‐Botet, J., Ascaso, J. F., Blasco, M., Brea, Á., Rodríguez, Á. D., Hernández‐Mijares, A., Pintó, X., & Millán, J. (2020) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2019.12.003 · Cited by 19
World Congress on Insulin Resistance, Diabetes, and Cardiovascular Disease
Bloomgarden, Z. T. (2011) · Diabetes Care · doi:10.2337/dc11-0840 · Cited by 10
Fibrates for secondary prevention of cardiovascular disease and stroke
Wang, D., Tao, W., Hao, Z., & Liu, M. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009580 · Cited by 11
Banach, M., Surma, S., Dzida, G. J., Jozwiak, J. J., Okopień, B., Rysz, J., Szosland, K., & Grzybowski, A. E. (2024) · Archives of Medical Science · doi:10.5114/aoms/197331 · Cited by 16
Yokote, K., Niwa, K., Hakoda, T., Oh, F., Kajimoto, Y., Fukui, T., Kim, H., Noda, Y., Lundström, T., & Yajima, T. (2020) · Circulation Journal · doi:10.1253/circj.cj-19-0358 · Cited by 7
The return of triglycerides and revival of omega-3 fatty acids!
Ferrières, J. (2020) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2020.04.004 · Cited by 7
Desouza, C. V. (2009) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmsott.s4170 · Cited by 13
Toth, P. P. (2009) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2009.02053.x · Cited by 7
Standl, E. (2012) · Diabetes and Vascular Disease Research · doi:10.1177/1479164112448876 · Cited by 7
Chen, Y. P., Chang, K.-C., Tseng, W., Yin, W. H., Chen, J., Lee, Y. T., & Wu, C. C. (2013) · Europe PMC (PubMed Central) · Cited by 7
López-Suárez, A., Bascuñana-Quirell, A., Beltrán-Robles, M., Elvira-González, J., Palacín, F. F., Barroso-Casamitjana, E., & Solino-Ocaña, I. (2014) · Medicine · doi:10.1097/md.0000000000000212 · Cited by 11
Chan, D. C., Pang, J., & Watts, G. F. (2016) · Springer eBooks · doi:10.1007/978-3-319-11251-0_30 · Cited by 11
What is new in lipid‐lowering therapies in diabetes?
Cheung, Y.-M. M., O’Brien, R., & Ekinci, E. I. (2019) · Internal Medicine Journal · doi:10.1111/imj.14291 · Cited by 8
Self-citationPerspectives on a new prescription omega-3 fatty acid, icosapent ethyl, for hypertriglyceridemia
Jacobson, T. A. (2014) · Clinical Lipidology · doi:10.2217/clp.14.10 · Cited by 6
Akbari, A., Islampanah, M., Arhaminiya, H., Fard, M. M. A., Jamialahmadi, T., & Sahebkar, A. (2023) · Current Medicinal Chemistry · doi:10.2174/0929867330666230413090416 · Cited by 8
Cziraky, M. J., Tan, H., Bullano, M. F., Yu, J. M., SCHIEBINGER, R. J., & Willey, V. J. (2011) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2011.02643.x · Cited by 6
Hypertriglyceridemic waist: missing piece of the global cardiovascular risk assessment puzzle?
Arsenault, B. J., Després, J., & Boekholdt, S. M. (2011) · Clinical Lipidology · doi:10.2217/clp.11.51 · Cited by 6
Critical review of non-statin treatments for dyslipoproteinemia
Pang, J., Chan, D. C., & Watts, G. F. (2014) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.2014.888312 · Cited by 7
Combination lipid therapy in type 2 diabetes mellitus
Vergès, B. L. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.558503 · Cited by 7
Drugs Targeting High-Density Lipoprotein Cholesterol for Coronary Artery Disease Management
Katz, P. M., & Leiter, L. A. (2012) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2012.03.017 · Cited by 7
Metabolic syndrome: Clinical perspective for best practice
Olde, D., Alpert, P. T., & Angosta, A. D. (2013) · Journal of the American Association of Nurse Practitioners · doi:10.1002/2327-6924.12048 · Cited by 10
Su, C., Chen, K. J., Sheu, W. H., Yang, Y. L., Liu, T.-J., Chang, W. C., Wang, K. Y., & Lee, W.-L. (2015) · Europe PMC (PubMed Central) · doi:10.6515/acs20150421a · Cited by 7
Management of Dyslipidemia in Type 2 Diabetes: Recent Advances in Nonstatin Treatment
Sugiyama, K., & Saisho, Y. (2018) · Diseases · doi:10.3390/diseases6020044 · Cited by 7
Chen, Y., Zhao, S., & Ye, H. (2020) · Current Medical Research and Opinion · doi:10.1080/03007995.2020.1747416 · Cited by 8
Lan, N. S. R., Burns, K. A., Bell, D. A., & Watts, G. F. (2020) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000594 · Cited by 6
Schade, D. S., Obenshain, S. S., Hickey, M., Febbo, J., Wann, S., & Eaton, R. P. (2022) · World Journal of Cardiovascular Diseases · doi:10.4236/wjcd.2022.126032 · Cited by 6
Halcox, J. (2013) · Clinical Lipidology · doi:10.2217/clp.13.16 · Cited by 6
Triglycerides and Cardiovascular Disease : A Scientific Statement From the
Pennathur, S., Kris‐Etherton, P. M., Lennie, T. A., Levi, M., Mazzone, T., Ginsberg, H. N., Goldberg, A. C., Howard, W. J., Stone, N. J., Ballantyne, C. M., et al. (2011) · Cited by 6
Sorokina, A. G., & Orlova, Y. A. (2019) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2019-11-142-147 · Cited by 8
Fibrate use in diabetes: New concepts
Bloomgarden, Z. T., & Drexler, A. (2010) · Journal of Diabetes · doi:10.1111/j.1753-0407.2010.00108.x · Cited by 6
New and Emerging Therapeutic Targets for ApoB-Containing Particles Lowering
Gaudet, D., Larouche, M., Raal, F. J., & Catapano, A. L. (2026) · Circulation Research · doi:10.1161/circresaha.126.327270 · Cited by 5
Advances in Lipid Testing and Management in Patients with Diabetes Mellitus
Vasudevan, M. M., & Ballantyne, C. M. (2009) · Endocrine Practice · doi:10.4158/ep09190.ra · Cited by 5
Lipids and cardiovascular disease 3 Triglycerides and cardiovascular disease
Nordestgaard, B. G., & Varbo, A. (2014) · Cited by 5
Cardiovascular outcomes trials with non-statin lipid-lowering drugs in diabetes
Naeem, F., McKay, G. A., & Fisher, M. (2018) · British Journal of Diabetes · doi:10.15277/bjd.2018.180 · Cited by 6
Krysiak, R. G., Kowalcze, K. E., & Okopień, B. (2020) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.13428 · Cited by 5
Management of Diabetes Mellitus
Jenkins, A. J., SCOTT, E. S., Fulcher, J., Kilov, G., & Januszewski, A. S. (2018) · Contemporary cardiology · doi:10.1007/978-3-319-97622-8_7 · Cited by 6
Current management of patients with nonalcoholic fatty liver disease
Elsheikh, E. B., Henry, L. L., & Younossi, Z. M. (2013) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.2013.846212 · Cited by 6
Managing the Dyslipidemia of Metabolic Syndrome: Beyond Statin Therapy
Jialal, I., & Smith, G. J. (2012) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2012.1500 · Cited by 5
Diabetes-Related Dyslipidemia and Cardiovascular Events
Fonseca, V. A., & Lovre, D. (2017) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2017.06.011 · Cited by 5
Fibrates : Do They Still Have a Role in Therapy in 2025?
Pirillo, A., Zambon, A., & Catapano, A. L. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01379-8 · Cited by 4
Hermans, M. P., Bouénizabila, E., Amoussou-Guénou, D., Ahn, S. A., & Rousseau, M. F. (2015) · Cardiovascular Diabetology · doi:10.1186/s12933-015-0226-z · Cited by 4
Triglycerides and Atherosclerotic Cardiovascular Disease.
Puri, R., Mehta, V., Iyengar, S. S., Narasingan, S. N., Duell, P. B., Sattur, G. B., Vijayaraghavan, K., Mohan, J. C., Wangnoo, S. K., Dalal, J. J., et al. (2020) · PubMed · Cited by 4
Guo, L., Zhu, L., Xu, J. R., Xie, Y., Xiang, Q., Jiang, Z.-Y., Tan, Y., & Liu, L. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.736059 · Cited by 4
Baragetti, A. (2022) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2022.09 · Cited by 5
Is there still a place for fenofibrate-statin combination therapy?
Farnier, M., Vrablík, M., & Catapano, A. L. (2023) · European Atherosclerosis Journal · doi:10.56095/eaj.v2i3.55 · Cited by 4
Heterogeneity of diabetic dyslipidemia, data from the NHANES (2011–2016)
Li, Y.-S., Liu, J., Huang, N., Cui, H., & Li, J. (2024) · Medicine · doi:10.1097/md.0000000000037173 · Cited by 4
Treatment of diabetic vasculopathy: an overview
Rahman, S., Majumder, & Rahman (2011) · Research and Reports in Endocrine Disorders · doi:10.2147/rred.s17512 · Cited by 4
Diabetic Dyslipidemia - Role of Saroglitazar
Majumder, A. (2014) · Medicinal Chemistry · doi:10.4172/2161-0444.1000212 · Cited by 7
Association of lipoprotein subclasses and carotid intima-media thickness in the Chinese population
Yan, F., Tian, L., Yu, H., Baskota, A., Gao, Y., Li, S., Fu, M., & Tian, H. (2014) · Clinical Lipidology · doi:10.2217/clp.14.22 · Cited by 4
Chan, D. C., Pang, J., & Watts, G. F. (2015) · Springer eBooks · doi:10.1007/978-3-319-12125-3_30-1 · Cited by 7
On P values and effect modification
Mayer, M. G. (2017) · International Journal of Evidence-Based Healthcare · doi:10.1097/xeb.0000000000000121 · Cited by 4
Peng, Y., Chen, G., & Zheng, H. (2020) · PubMed · doi:10.12122/j.issn.1673-4254.2020.08.11 · Cited by 6
Ginsberg, H. N., Khavandi, M., & Reyes‐Soffer, G. (2020) · Endocrinology · doi:10.1007/978-3-030-36694-0_2 · Cited by 4
Pedro‐Botet, J., Ascaso, J. F., Blasco, M., Brea, Á., Díaz, Á., Hernández‐Mijares, A., Pintó, X., & Millán, J. (2020) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2019.12.001 · Cited by 7
Fibrate Therapy in the Management of Diabetic Dyslipidemia: There is No ACCORD to be Found
Toth, P. P. (2010) · Current Atherosclerosis Reports · doi:10.1007/s11883-010-0126-3 · Cited by 4
Lee, S. Y., Koo, B. K., & Moon, M. K. (2017) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2016.285 · Cited by 5
Metadata
- Authors
- Scott, R., O'Brien, R., Fulcher, G., Pardy, C., d'Emden, M., Tse, D., Taskinen, M.-R., Ehnholm, C., Keech, A., & on behalf of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study Investigators
- Affiliations
- Christchurch Hospital (NZ)
- Department of Medicine, Austin Hospital, University of Melbourne, Melbourne, Australia
- The University of Sydney (AU)
- Endocrine Research Unit, Royal Brisbane Hospital, Brisbane, Australia
- Helsinki University Hospital (FI)
- Department of Molecular Medicine, National Public Health Institute, Biomedicum, Helsinki, Finland
- Corresponding author
- Scott, Russell
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2009-03-01
- Volume
- 32
- Issue
- 3
- Pages
- 493-498
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC2646035
- OpenAlex
- W1975018096
- Cited by
- 551
- References
- 26
- Citations by year
- 2026: 10 · 2025: 13 · 2024: 15 · 2023: 20 · 2022: 12 · 2021: 23 · 2020: 32 · 2019: 34 · 2018: 28 · 2017: 31 · 2016: 32 · 2015: 43 · 2014: 41 · 2013: 41 · 2012: 38
- FWCI
- 33.39
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Minerva Access (University of Melbourne) (submittedVersion, cc-by-nc-nd)
- Funders
- Medical Research Council
- National Health and Medical Research Council
- National Medical Research Council
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- fenofibrate, type 2 diabetes, metabolic syndrome, cardiovascular risk, hypertriglyceridemia, dyslipidemia, low HDL cholesterol, hypertension, field trials, NCEP ATP III criteria
- MeSH terms
- Hypolipidemic Agents, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Female, Humans, Male, Fenofibrate, Metabolic Syndrome, Dyslipidemias
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.